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Results
Base Case Model Outcomes:
  •  SFGC and epoetin costs $3675.36 per g/dL increase in Hb.
  •  Epoetin alone costs $5064.68 per g/dL increase in Hb.
  •   Adding SFGC to epoetin provided a savings of $1389.32 for each g/dL increase in 
Hgb.
  •  The rolled back model with calculations is presented in Figure 2.
Univariate Sensitivity Analysis:
  •   The model was robust to sensitivity analyses which included  
modifications to:
 –  Study population
 –  Adverse event costs
 –  Treatment efficacies
 –  Medication costs, with one exception:
        •   When the magnitude of the additional medication costs exceeded the savings 
associated with decreased adverse events, the cost of SFGC and epoetin 
combined was greater than that of epoetin alone.  This was the case when the 
national reimbursement rates (at the 25th or 85th percentile) were used instead 
of Medicare reimbursement rates.
Probabilistic Sensitivity Analysis:
  •   Results of the probabilistic sensitivity analysis demonstrate that the combination of 
SFGC and epoetin tended to be the more cost effective than epoetin alone.  
  •   The scatterplot in Figure 3 illustrates the extent of the variability in the model 
determined using the Monte Carlo simulation.  The origin represents the relative 
cost and efficacy of epoetin alone and each point represents the comparative cost 
effectiveness of epoetin and SFGC in combination.  
 –   The 95% confidence interval includes the origin, so we cannot say with certainty 
that SFGC and epoetin dominates epoetin alone.  
 –   32.53% of the points are in the lower left hand portion of the graph, representing 
the dominance of SFGC and epoetin in combination
 –   18.49% of points in the upper left corner representing the dominance of epoetin 
alone
 –   48.98% of points are in the two quadrants where a decision has to be made 
regarding an increased cost for increased efficacy.
Discussion
We believe this is a conservative model for the following reasons:
  •   Epoetin doses were flexible only during DRIVE II (the last 6 weeks of our model’s time 
horizon), which limited the opportunity to observe a long-term difference in epoetin 
usage.
  •   Data on epoetin dosing were not available during patient hospitalizations.  Since the 
rate and duration of hospitalizations were slightly higher in the epoetin only group 
and patients dropped out of the study if hospitalized because of a serious adverse 
event (the rate of which was significantly higher for the epoetin only group), it is 
likely that the true amount of epoetin administered to both groups exceeds our 
available data and is higher for the epoetin alone than the SFGC and epoetin group.
Study limitations:
  •   Because this model is based on protocol-driven clinical trial data, it does not 
accurately depict actual clinical practice.  Future studies using observational data are 
essential to confirm these findings.
  •   The model considered only costs associated with serious adverse events.
Conclusions
This cost-effectiveness analysis of the DRIVE studies data suggests that administering 
1 gram of SFGC to patients with high ferritin and TSAT of 25% or less results in cost 
savings when the Medicare perspective is employed. 
When incorporated into a decision-analytic model, SFGC and epoetin treatment was 
estimated to result in a savings of $1389 per gram/dL of hemoglobin increase, which we 
believe to be conservative due to the fixed doses of epoetin required during the first 6 
weeks of DRIVE.  
Though there is uncertainty surrounding any economic analysis, our findings suggest 
that administering SFGC to this subset of anemia patients represents one potential 
strategy for reducing treatment costs in Medicare patients. 
Application of our model to a population-level database is worthwhile to determine if 
findings hold true in actual practice.
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Table 1:  Assigned DRG codes and estimated costs* 
Treatment Adverse Event  
Description
Assigned DRG 
Code
Assigned DRG Description Estimated 2007 Reimburse-
ment for This DRG ($US)
SFGC and Epoetin Syncope 141 Syncope and Collapse with CC 3,720.45
Abdominal Pain NOS 463 Signs and Symptoms with CC 3,491.67
Endocarditis NOS 126 Acute and Subacute Endocarditis 12,986.21
Implant Infection 120 Other Circulatory System O.R. Procedures 11,777.93
Kidney Transplant 
Rejection
442 Other O.R. Procedures for Injuries with CC 12,446.22
Cardiac Arrest 121 Circulatory Disorders with Acute Myocardial Infarction and Major 
Complications, Discharged Alive
7,883.34
Hypertension NOS 134 Hypertension 3,020.95
Cardiac Failure  
Congestive
127 Heart Failure and Shock 5,114.58
Skin and Subcutaneous 
Tissue Abcess
277 Cellulitis, Age Greater than 17 with CC 4,365.81
Clotted Tesio Catheter 317 Admission for Renal Dialysis 3,935.08
Gangrene 130 Peripheral Vascular Disorders with CC 4,736.05
Fluid Overload 317 Admission for Renal Dialysis 3,935.08
Pleural Effusion 85 Pleural Effusion with CC 6,076.52
Coagulation Time NOS 
Prolonged
397 Coagulation Disorders 6,477.98
Implant Infection 120 Other Circulatory System O.R. Procedures 11,777.93
Congestive Cardiac 
Failure Aggravated
317 Admission for Renal Dialysis 3,935.08
Hypoglycemia NOS 296 Nutritional and Miscellaneous Metabolic Disorders, Age Greater than 
17 with CC
4,065.33
Epoetin Alone Peritonitis 572 Major Gastrointestinal Disorders and Peritoneal Infections 6,525.79
Gastric Erosions 182 Esophagitis, Gastroenteritis and Miscellaneous Digestive Disorders, 
Age Greater than 17 with CC
3,831.67
Nodal Arrythmia 138 Cardiac Arrhythmia and Conduction Disorders with CC 4,079.47
Sepsis NOS 120 Other Circulatory System O.R. Procedures 11,777.93
Pancreatitis Acute 204 Disorders of Pancreas Except Malignancy 5,360.43
Cerebrovascular  
Accident
14 Intracranial Hemorrhage or Cerebral Infarction 5,907.25
Cardiac Failure  
Congestive
127 Heart Failure and Shock 5,114.58
Pneumonia NOS 89 Simple Pneumonia and Pleurisy, Age Greater than 17 with CC 5,061.41
Pneumonia  
Staphylococcal
565 Respiratory System Diagnosis with Ventilator Support < 96 Hours 25,509.01
Pulmonary Edema 87 Pulmonary Edema and Respiratory Failure 6,748.71
Colitis Ischemic 182 Esophagitis, Gastroenteritis and Miscellaneous Digestive Disorders, 
Age Greater than 17 with CC
3,831.67
Cardiac Failure  
Congestive
127 Heart Failure and Shock 5,114.58
Dyspnea NOS 317 Admission for Renal Dialysis 3,935.08
Cellulitis 277 Cellulitis, Age Greater than 17 with CC 4,365.81
Skin and Subcutaneous 
Tissue Abcess
277 Cellulitis, Age Greater than 17 with CC 4,365.81
Failure to Thrive 172 Digestive Malignancy with CC 6,965.78
Sepsis NOS 576 Septicemia without Ventilator Support 96+ Hours, Age Greater 
than 17
7,781.87
Blood Culture Positive 576 Septicemia without Ventilator Support 96+ Hours, Age Greater 
than 17
7,781.87
Cellulitis 277 Cellulitis, Age Greater than 17 with CC 4,365.81
Pulmonary Edema NOS 87 Pulmonary Edema and Respiratory Failure 6,748.71
Sepsis NOS 120 Other Circulatory System O.R. Procedures 11,777.93
Fluid Overload 317 Admission for Renal Dialysis 3,935.08
*NOS: not otherwise specified; CC: complicating condition
Table 2:  Values used for each model input , base case and sensitivity analyses*
Model Version
Model 
Arm
Variable Base Case Modified 
Study Popula-
tion
Modified Adverse Event Costs Modified Medication Costs Modified Treatment Efficacies
2005 Actual 
Hospitaliza-
tion Costs
Fixed Hospital 
Cost per Day
Median Medi-
cation Usage
25th Percentile 
Medication 
Costs
85th Percentile 
Medication 
Costs
Median Treat-
ment Efficacy
Treatment 
Efficacy 
- 1 Standard 
Deviation
Treatment 
Efficacy + 
1 Standard 
Deviation
Iron and 
Epoetin
Cost of Iron $499.13 $499.82 $499.13 $499.13 $457.92 $1,151.04 $1,988.16 $499.13 $499.13 $499.13
Cost of Epoetin $4,031.78 $4,144.26 $4,031.78 $4,031.78 $3,554.73 $7,346.23 $12,963.93 $4,031.78 $4,031.78 $4,031.78
Cost of Adverse Events $6,455.66 $6,742.66 $7,335.16 $10,042.69 $6,455.66 $6,456.66 $6,457.66 $6,455.66 $6,455.66 $6,455.66
Probability of Adverse Events 26.60% 25.90% 26.60% 26.60% 26.60% 26.60% 26.60% 26.60% 26.60% 26.60%
Treatment Efficacy 1.7g/dL 1.8 1.7g/dL 1.7g/dL 1.7g/dL 1.7g/dL 1.7g/dL 1.5 0.3 3.1
Epoetin 
Alone
Cost of Iron $50.28 $48.20 $50.28 $50.28 $0.00 $115.96 $200.29 $50.28 $50.28 $50.28
Cost of Epoetin $4,248.92 $4,331.55 $4,248.92 $4,248.92 $3,892.94 $7,741.54 $13,662.12 $4,248.92 $4,248.92 $4,248.92
Cost of Adverse Events $6,858.47 $6,980.93 $7,314.61 $14,346.70 $6,858.47 $6,859.47 $6,860.47 $6,858.47 $6,858.47 $6,858.47
Probability of Adverse Events 33.80% 33.30% 33.80% 33.80% 33.80% 33.80% 33.80% 33.80% 33.80% 33.80%
Treatment Efficacy 1.3g/dL 1.4 1.3g/dL 1.3g/dL 1.3g/dL 1.3g/dL 1.3g/dL 1.3 -0.3 2.9
*Highlighted cells indicate the values that are different from the base case in each of the univariate sensitivity analyses
Table 3: Results from the univariate sensitivity analyses
Model Version Cost Effectiveness Ratio ICER*
SFGC and Epoetin 
Arm (cost per g/dL 
increase in Hb)
Epoetin 
Alone Arm           
(cost per g/dL 
increase in 
Hb)
Base Case $3,675.36 $5,064.68 SFGC and Epoetin  
Dominates Epoetin Alone
Modified Study Population
(Using DRIVE II Safety Population vs. the 
DRIVE I ITT population)
$3,523.46 $5,064.67 SFGC and Epoetin  
Dominates Epoetin Alone
Modified Hospitalization Costs (used 2005 
Actual reimbursements)
$3,812.98 $5,183.27 SFGC and Epoetin  
Dominates Epoetin Alone
Employed Fixed Hospital Cost per Day $4,236.63 $7,011.61 SFGC and Epoetin  
Dominates Epoetin Alone
Employed Median Medication Usage $3,370.50 $4,777.77 SFGC and Epoetin  
Dominates Epoetin Alone
Applied 25th Percentile Medication Costs $7,768.38 $6,008.52 $288.95 per additional g/dL increase in Hb
Applied 85th Percentile Medication Costs $12,344.60 $9,805.47 $1553.29 per additional g/dL increase in Hb
Used Median Treatment Efficacy $4,165.41 $5,064.67 SFGC and Epoetin  
Dominates Epoetin Alone
Treatment Efficacy - 1 Standard Deviation $20,827.05 -$21946.92** SFGC and Epoetin Dominates Epoetin Alone
Treatment Efficacy + 1 Standard Deviation $2,015.52 $2,270.37 SFGC and Epoetin Dominates Epoetin Alone
*If one treatment option is both less costly, and more effective, the ICER will be calculated as a negative number.  When this happens, it 
is most appropriate to simply report that one treatment option dominates the other.
**Because epoetin alone actually had negative efficacy in this analysis, the cost effectiveness ratio was also negative.
Figure 3
Figure 1: Decision Tree Framework
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Figure 2: Results of Decision Tree after Roll-Back Calculations
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Abstract
Purpose: One third of hemodialysis patients have high serum ferritin levels and low  transferrin saturation (TSAT). The purpose of this analysis was 
to determine the cost effectiveness of administering 1g of sodium ferric gluconate complex (SFGC: also referred to as ferric gluconate) to patients 
with serum ferritin >500ng/mL and TSAT ≤25% based on the Dialysis Patients  Response to IV Iron with Elevated Ferritin (DRIVE) study and its 6-week 
observational extension (DRIVE-II). In these studies, IV iron administration resulted in reduced epoetin requirements.
Methods: Decision analysis was performed using a time horizon of 12 weeks, consistent with the combined duration of DRIVE and DRIVE II. 
Treatment effectiveness was based on mean increase in hemoglobin (Hb) for each group (SFGC plus epoetin or epoetin alone) in the intention to 
treat populations. Costs included drugs (SFGC and epoetin) and hospitalizations due to serious adverse events (SAEs) reported. The primary cost 
effectiveness measure was cost per g/dL of Hb increase at 12 weeks. Costs were computed from a Medicare perspective using projected 2007 
reimbursements. Sensitivity analyses were performed to test the impact of using the safety population, median epoetin and SFGC doses, actual 2005 
Medicare reimbursements, median increases in Hb, and SAE rate changes. The model was constructed using TreeAge Pro software. 
Results: Total cost per patient receiving SFGC plus epoetin was $3675 per g/dL Hb increase, while the total cost per patient receiving epoetin alone 
was $5065 per g/dL Hb increase. Net savings for SFGC plus epoetin was $1390 per g/dL Hb increase over the 12 week period Sensitivity analyses
affirmed the robustness of the model. 
Conclusion: Administering 1g of SFGC plus epoetin in patients with high ferritin and low TSAT as defined in the DRIVE studies resulted in significant 
cost-savings compared to epoetin alone. 
Background
Significant policy issues surround the management of anemia with epoetin and iron;
  •  Medicare is developing a bundled payment scheme for dialysis services
  •  The safety of epoetin has been called into question1
The DRIVE Studies were conducted to determine the best treatment options for a subgroup of anemic 
end stage renal disease (ESRD) patients with high ferritin, but low to low-normal TSAT levels
  •  DRIVE I:
 –  A 6 week randomized controlled trial
 –  Measured the effect of adding SFGC to epoetin
 –   Patients included in this trial were on hemodialysis, anemic (Hb < 11g/dL) despite an epoetin 
dosage >22,500 IU/week (or >225 IU/kg per week), and had high ferritin (500-1200ng/mL) and low 
TSAT (≤25%) measures
 –   The intent to treat population included 64 participants in the SFGC and epoetin group, and 65 
participants in the epoetin alone group
 –   Patients were prescribed set doses of epoetin, 25% greater than their pre-trial dosing
 –   This study found that patients receiving SFGC had significantly greater increases in Hb than those 
who did not2
  •  DRIVE II:
 –   A 6 week observational follow-up study to DRIVE
 –   During this phase of the trial, physicians were free to adjust epoetin doses as they saw fit
 –   At the conclusion of this trial, patients who had received SFGC during DRIVE I received less 
epoetin on average, and experienced a greater increase in their Hb levels3
Objective
To determine if the addition of SFGC to epoetin is cost effective for anemic hemodialysis patients with 
high ferritin and low TSAT.
Methods
Model Design:
  •  A cost effectiveness analysis was conducted utilizing a decision tree framework
  •  Cost effectiveness was measured as the cost per unit of Hb increase observed in the DRIVE studies for 
the SFGC plus epoetin versus epoetin alone, and reported using the incremental cost effectiveness  
ratio (ICER)
  •  This model used the perspective of a Medicare payer because that program bears a majority of the cost 
of ESRD treatment in the U.S.
  •  The model was constructed to simulate the treatment groups in the DRIVE studies
  •  Data from the DRIVE studies were used to populate the variables in the model
  •  The model is presented in Figure 1
Assumptions and Costing Procedures:
  •  Hospitalizations associated with serious adverse events (SAEs) were coded using diagnosis related 
groupings (DRGs). The average national reimbursement for each DRG was then used to estimate the cost 
for each SAE. The DRG codes applied and estimated costs are listed in Table 1.
  •  Current Medicare reimbursement levels were used to estimate the cost of epoetin and SFGC based on 
the mean dose of medication used.
  •  Adverse event probabilities were based on the percent of patients hospitalized for a SAE in each group.
  •  Treatment efficacies were based on the mean change in Hb level from baseline to week 12 (the 
beginning of DRIVE I to the end of DRIVE II).
Sensitivity Analyses
•   Univariate (one –way) Sensitivity Analyses
 –   Each variable was replaced individually with a range of possible values.  These values are listed in 
Table 2.
•   Probabilistic Sensitivity Analysis
 –   Simulations of this model were run taking into account the estimated variability around each input.
 –   Simulations were run using a Monte Carlo method, to test 1 million random iterations of the model. 
  Results of the Probabilistic Sensitivity Analysis, showing the incremental 
cost effectiveness scatterplot of SFGC and epoetin versus epoetin alone 
based on 1 million random iterations of the cost-effectiveness model 
(Monte Carlo simulation)
Probability = 73.4%
Probability = 66.2%
